SCHEMBL7525385

SCHEMBL7525385

O=C1NC(=O)/C(=C\c2ccc(-c3nc4cc(Cl)c(Cl)cc4n3Cc3ccc4ccccc4c3)cc2)S1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGAM O43451 2/20 0.69
GAA P10253 2/20 0.69
SI P14410 2/20 0.69
MGAM2 Q2M2H8 2/20 0.69
KCNH2 Q12809 1/20 0.50
BRD4 O60885 1/20 0.46
RHEB Q15382 1/20 0.44
IGF1R P08069 1/20 0.44
HPGD P15428 4/20 0.44
GSK3B P49841 1/20 0.43
PARP1 P09874 3/20 0.42
PTPN1 P18031 2/20 0.42
CNR1 P21554 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
MEN1 O00255 1/20 0.41
PIM1 P11309 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7525388 1.00 MGAM (0.69) MGAMGAASIMGAM2KCNH2
SCHEMBL7515222 0.92 MGAM (0.72) MGAMGAASIMGAM2KCNH2
SCHEMBL7515220 0.92 MGAM (0.72) MGAMGAASIMGAM2KCNH2
SCHEMBL7514352 0.91 MGAM (0.68) MGAMGAASIMGAM2KCNH2
SCHEMBL7514347 0.91 MGAM (0.68) MGAMGAASIMGAM2KCNH2
SCHEMBL7521205 0.86 MGAM (0.63) MGAMGAASIMGAM2KCNH2
SCHEMBL7521202 0.86 MGAM (0.63) MGAMGAASIMGAM2KCNH2
SCHEMBL7510191 0.86 MGAM (0.82) MGAMGAASIMGAM2KCNH2
SCHEMBL7512735 0.86 MGAM (0.82) MGAMGAASIMGAM2KCNH2
SCHEMBL7510551 0.84 MGAM (0.65) MGAMGAASIMGAM2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 MGAM 3441/4885GAA 625/4885SI 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.